Trial Profile
A 12-week, double-blind, placebo-controlled, randomized, multicenter study of the efficacy of doses of 20 and 60 mg/day istradefylline as treatment for Parkinson's disease in patients with motor response complications on levodopa/carbidopa
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 24 Jul 2023
Price :
$35
*
At a glance
- Drugs Istradefylline (Primary)
- Indications Parkinson's disease
- Focus Therapeutic Use
- Sponsors Kyowa Kirin; Kyowa Kirin Pharmaceutical Development
- 03 Jun 2008 Results were published in Neurology.
- 17 Apr 2007 New trial record.